ClinicalTrials.gg
RecruitingNCT07948330RESTOREUpdated Nov 19, 2026

rTMS for Incontinence After Prostate Treatment

An interventional study of Magstim - rTMS system and Baseline Imaging and Questionnaires in Urinary Incontinence, Prostate Treatment and Incontinence After Prostate Treatment, sponsored by The Methodist Hospital Research Institute. Recruiting at 1 site in United States. Open to male participants aged 22 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by The Methodist Hospital Research Institute · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
22 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 293 studies in Urinary Incontinence with a site in United States — 33 open to participants now, 47 under way, 3 of them phase 3. Urinary Incontinence · United States.

Planned enrollment
194th of 249
23 · median 75
Started
2026
with 10 others
No phase
144 of 293
21 open now
Primary completion
2027-10
later than 32 of 46 live
Registered
293rd of 293
by date

Among the 293 studies in Urinary Incontinence with a site in United States, this one is the 194th largest by planned enrollment of the 249 interventional ones that give a count, is one of 11 that started in 2026, is one of 144 with no phase, reaches primary completion later than 32 of the 46 other live ones, and was the 293rd registered.

Urinary Incontinence

988 studies on the registry are indexed under Urinary Incontinence; 184 are open to participants now.

Browse Urinary Incontinence studies →

Open to participants now

33 of the 293 studies in Urinary Incontinence with a site in United States are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 113 Urinary Incontinence studies recruiting now, 63 (56%) set no upper age limit and 35 (31%) stop at 75 or younger; 15 take children under 18; 28 take healthy volunteers.

This study: 22 Years to 80 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Urinary Incontinence with a site in United States, or all of them as a file.
02

Study summary

Incontinence after prostate treatment (IPT) affects up to 25% of men following radical prostatectomy or other prostate therapies, primarily resulting from sphincteric weakness and impaired neuromuscular control. Current management options, including behavioral therapy and surgical implants, are often limited by modest effectiveness or invasiveness. Emerging neuroimaging evidence demonstrates that the pelvic supplementary motor area (pSMA) in the brain plays a critical regulatory role in controlling pelvic floor muscles and urethral sphincter activity. This proof-of-concept, prospective, randomized clinical trial aims to evaluate the safety, tolerability, acceptability, and procedural feasibility of targeting the pSMA using non-invasive repetitive transcranial magnetic stimulation (rTMS) in adult males with IPT, alongside a cohort of continent controls. A total of 23 participants will be enrolled (targeting 10 evaluable IPT subjects and 10 continent controls). Participants undergo baseline fMRI using a natural bladder filling protocol, and a randomized, single-session neuronavigated rTMS protocol with concurrent pelvic floor electromyography (EMG) and functional Magnetic Resonance Imaging (fMRI) to evaluate physiological and neurofunctional changes. Safety and adverse events are monitored closely through a 1-month virtual follow-up visit. Findings from this study will establish foundational evidence for cortical modulation of pelvic floor control in IPT. Additionally, these results will guide the design of a future larger, clinical trial to optimize rTMS parameters and integrate brain neuromodulation into post-prostate treatment rehabilitation strategies.

Read the detailed description

Incontinence after prostate treatment (IPT) affects up to 25% of men following radical prostatectomy or other prostate therapies, primarily resulting from sphincteric weakness and impaired neuromuscular control. Current management options, including behavioral therapy and surgical implants, are often limited by modest effectiveness or invasiveness. Emerging neuroimaging evidence demonstrates that the pelvic supplementary motor area (pSMA) in the brain plays a critical regulatory role in controlling pelvic floor muscles and urethral sphincter activity. This proof-of-concept, prospective, randomized clinical trial aims to evaluate the safety, tolerability, acceptability, and procedural feasibility of targeting the pSMA using non-invasive repetitive transcranial magnetic stimulation (rTMS) in adult males with IPT, alongside a cohort of continent controls. A total of 23 participants will be enrolled (targeting 10 evaluable IPT subjects and 10 continent controls). Participants undergo baseline fMRI using a natural bladder filling protocol, and a randomized, single-session neuronavigated rTMS protocol with concurrent pelvic floor electromyography (EMG) and functional Magnetic Resonance Imaging (fMRI) to evaluate physiological and neurofunctional changes. Safety and adverse events are monitored closely through a 1-month virtual follow-up visit. Findings from this study will establish foundational evidence for cortical modulation of pelvic floor control in IPT. Additionally, these results will guide the design of a future larger, clinical trial to optimize rTMS parameters and integrate brain neuromodulation into post-prostate treatment rehabilitation strategies. Study Objectives: Aim 1: Assess the safety, tolerability, acceptability (measured via the Acceptability of Intervention Measure [AIM] questionnaire), and procedural feasibility of performing pSMA-targeted rTMS, concurrent pelvic floor electromyography (EMG), and functional Magnetic Resonance Imaging (fMRI) in men with IPT. Aim 2: Evaluate the physiological and neurofunctional effects of excitatory (high-frequency) and inhibitory (low-frequency) rTMS on pSMA activity (assessed via BOLD signal changes on fMRI) and pelvic floor muscle tone (assessed via EMG amplitudes). Aim 3: Compare baseline pSMA activity (BOLD signal on fMRI) and functional connectivity during natural bladder filling between continent post-prostate-treatment controls and men with IPT. Study Design \& Procedures:

This single-center, prospective, randomized trial enrolls 23 participants (10 IPT subjects and 10 continent controls evaluable). Participants attend up to 5 scheduled visits over 6 to 8 weeks (4 to 6 weeks for controls): Visits 1 \& 2 (Screening \& Baseline): Informed consent, cognitive assessment (MoCA), medical history, baseline urological questionnaires (AUA-SS, ICIQ-UI SF), bladder diaries, and baseline diagnostics (uroflow, PVR, urinalysis). Visit 3 (Baseline Imaging): Anatomical and functional brain MRI (3T or 7T) with a natural bladder filling protocol to map pSMA coordinates. For continent controls, study participation concludes after Visit 3. Visit 4 (Intervention \& Post-Scan - IPT Cohort Only): Randomization 1:1 to either high-frequency (Arm 1) or low-frequency (Arm 2) rTMS delivered via the Magstim Rapid2 system and neuronavigation. Perineal EMG records muscle activity during standardized Kegel exercises, followed immediately by post-intervention fMRI and the AIM acceptability questionnaire. Visit 5 (Follow-Up - IPT Cohort Only): A 1-month virtual safety check-in to monitor for delayed adverse events. Study Endpoints: Primary Endpoints: Recruitment/retention rates, participant acceptability (AIM scores), and incidence/severity of adverse events. Secondary Endpoints: Changes in BOLD signal activity and EMG amplitudes following rTMS, and baseline functional connectivity differences between IPT subjects and continent controls.

03

Conditions studied

  • Urinary Incontinence
  • Prostate Treatment
  • Incontinence After Prostate Treatment

Browse trials for

Keywords

  • functional neuroimaging
  • repetitive transcranial magnetic stimulation
  • neuromodulation
04

Who can participate

Ages eligible
22 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria (IPT Cohort):

  • Adult males (biological sex at birth), aged 22 to 80 years.
  • History of prostate treatment (e.g., radical prostatectomy, TURP, HoLEP, Aquablation, water vapor therapy, photoselective vaporization) ≥ 6 months prior.
  • Answers "yes" to any sub-item of Question 6 on the ICIQ-UI SF ("When does urine leak?", such as leaks before reaching the toilet, cough/sneeze, during sleep, physical activity, post-void dribbling, or no obvious reason).
  • (MoCA) score > 10.
  • Eligible per MRI safety screening questionnaire.

Inclusion Criteria (Continent Control):

  • Adult males (biological sex at birth), aged 22 to 80 years.
  • History of prostate treatment ≥ 6 months prior.
  • Selects only "never - urine does not leak" on Question 6 of the ICIQ-UI SF and has a total score = 0.
  • Montreal Cognitive Assessment (MoCA) score > 10.
  • Eligible per MRI safety screening questionnaire.

Exclusion Criteria:

  • Answers "never" to Question 6 of the ICIQ-UI SF (for IPT cohort) or answers "yes" to any sub-item (for continent cohort).
  • to MRI.
  • Contraindications to rTMS (personal or immediate family history of seizure disorder, implanted electronic devices or conductive objects in or near the head).
  • Active urinary tract infection (UTI) at screening (eligible after adequate treatment).
  • Intradetrusor onabotulinumtoxinA injection within the past 6 months.
  • Active use of sacral neurostimulator (SNS) or posterior tibial nerve stimulation (TNS) (history allowed if last stimulation was > 3 months prior).
  • Clinically diagnosed neurological disorders (e.g., Multiple Sclerosis, Parkinson's disease, cerebral aneurysm, hydrocephalus, spinal cord injury with motor/sensory deficits, or advanced dementia defined by MoCA > 10).
  • Parenchymal brain lesions and hemorrhagic stroke within the last 12 months. Taking medications that lower seizure threshold (e.g., bupropion) or heavy alcohol use.
  • Diagnosis of interstitial cystitis, history of pelvic radiation, or bladder augmentation.
  • Post-void residual (PVR) > 250 cc.
  • Incarcerated individuals.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
23 participants (estimated)

Study arms

  • Experimental
    High-Frequency rTMS (Excitatory)

    Participants receive high-frequency (excitatory) repetitive transcranial magnetic stimulation (rTMS) targeted at the pelvic supplementary motor area (pSMA) for 20 minutes total.

    Device: Magstim - rTMS system

  • Experimental
    Low-Frequency rTMS (Inhibitory)

    Participants receive low-frequency (inhibitory) repetitive transcranial magnetic stimulation (rTMS) targeted at the pelvic supplementary motor area (pSMA) for 20 minutes.

    Device: Magstim - rTMS system

  • Other
    Continent Controls

    Non-interventional Control Group undergoing questionnaires and baseline imaging (fMRI)

    Other: Baseline Imaging and Questionnaires

Interventions

  • DeviceMagstim - rTMS system

    The Magstim Rapid2 system is a magnetic stimulation system capable of selectively inducing, modulating, or suppressing neuronal activity. This rTMS device will be used along with the D70 Alpha Coil package, which includes an active coil ideal for focal rTMS. Utilizing the StimGuide navigation system, the investigators will accurately target the pelvic supplementary motor area (pSMA). The Magstim Rapid2 system is used in this study to deliver either high-frequency (excitatory) or low-frequency (inhibitory) rTMS to assess physiological and neurofunctional effects on continence control in men with incontinence after prostate treatment (IPT).

  • OtherBaseline Imaging and Questionnaires

    Non-interventional control consistent of questionnaires and baseline brain functional MRI (fMRI) with no rTMS stimulation.

06

What researchers measure

Primary outcomes

  1. Recruitment and Retention Rate

    Evaluation of study feasibility by tracking the proportion of participants successfully enrolled in the study compared to those lost to follow-up or withdrawn prior to completion.

    Time frame: From enrollment through the 1-month follow-up visit (approximately 2 to 3 months total per participant)

  2. Acceptability of Intervention

    Participant acceptability, feasibility, and practicality evaluated using the Acceptability of Intervention Measure (AIM) questionnaire.

    Time frame: Immediately after the single rTMS treatment session (Visit 4 : 3 weeks +/- 2 weeks after enrollment)

  3. Adverse Events

    The incidence of all patient- or physician-reported adverse events (AEs) related to the procedure, device, and/or stimulation occurring throughout the study duration.

    Time frame: From informed consent through the 1-month virtual follow-up visit

Secondary outcomes

  1. pSMA Activity

    Changes in blood-oxygen-level-dependent (BOLD) signals within the pelvic supplementary motor area (pSMA) assessed via functional MRI between baseline and post-treatment scans.

    Time frame: Baseline (Visit 3) and post rTMS treatment fMRI on the day of rTMS session (Visit 4: 3 weeks +/- 2 weeks after enrollment)

  2. Pelvic Floor Muscle Tone

    Changes in pelvic floor muscle (PFM) tone assessed via perineal surface electromyography (EMG) amplitudes recorded at rest, during standardized Kegel exercises, and after each corresponding rTMS pulse train.

    Time frame: During the 20-minute rTMS treatment session (Visit 4 : 3 weeks +/- 2 weeks after enrollment)

  3. Baseline Functional Connectivity

    Differences in baseline pSMA BOLD signal and functional connectivity during natural bladder filling between men with incontinence after prostate treatment (IPT) and continent controls (CC).

    Time frame: Baseline imaging session (Visit 3)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Khavari R, Tran K, Helekar SA, Shi Z, Karmonik C, Rajab H, John B, Jalali A, Boone T. Noninvasive, Individualized Cortical Modulation Using Transcranial Rotating Permanent Magnet Stimulator for Voiding Dysfunction in Women with Multiple Sclerosis: A Pilot Trial. J Urol. 2022 Mar;207(3):657-668. doi: 10.1097/JU.0000000000002297. Epub 2021 Oct 25. PubMed 34694911 ↗
  • Griffiths D. Neural control of micturition in humans: a working model. Nat Rev Urol. 2015 Dec;12(12):695-705. doi: 10.1038/nrurol.2015.266. Epub 2015 Dec 1. PubMed 26620610 ↗
  • Yani MS, Fenske SJ, Rodriguez LV, Kutch JJ. Motor cortical neuromodulation of pelvic floor muscle tone: Potential implications for the treatment of urologic conditions. Neurourol Urodyn. 2019 Aug;38(6):1517-1523. doi: 10.1002/nau.24014. Epub 2019 May 1. PubMed 31044482 ↗
  • Breyer BN, Kim SK, Kirkby E, Marianes A, Vanni AJ, Westney OL. Updates to Incontinence After Prostate Treatment: AUA/GURS/SUFU Guideline (2024). J Urol. 2024 Oct;212(4):531-538. doi: 10.1097/JU.0000000000004088. Epub 2024 Jun 27. PubMed 38934789 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Of 303 non-industry interventional studies with no phase under Urinary Incontinence, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 366 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 19, 2026
StartActual
Sep 16, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948330
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Sep 16, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Rose Khavari, MD
Contact
rkhavari@houstonmethodist.org
7133700660
Kelly Ieong, MD
Contact
kieong@houstonmethodist.org
Rose Khavari, MD
principal investigator · The Methodist Hospital Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion